Genomic impact of outcomes in MF patients undergoing allo-HCT
Lead author/ reference . | Disease and no. of patients . | No. of genes tested . | Conditioning regimen . | Survival data . | Notes . |
---|---|---|---|---|---|
Kröger 201730 | 169 MF patients who underwent allo-HCT | 16 | MAC: 2% RIC: 98% | 5-y PFS = 48% 5-y OS = 52% | CALR mutation associated with improved OS IDH2 mutation associated with inferior RFS ASXL1 mutation associated with inferior RFS |
Tamari 201932 | 101 MF patients who underwent allo-HCT | 585 | MAC: 18% RIC: 82% | 5-y RFS = 51% 5-y OS = 52% | U2AF1 mutation associated with inferior OS and RFS DNMT3A mutation associated with inferior RFS ≥3 somatic mutations not associated with worse OS compared with ≤2 somatic mutations MAC associated with improved OS High-risk MIPSS70 not associated with inferior OS compared with intermediate-risk MIPSS70 |
Ali 201933 | 110 MF patients who underwent allo-HCT | 72 | RIC: 100% | 5-y PFS = 60% 5-y OS = 65% | CBL mutation associated with inferior OS and DFS U2AF1 mutation associated with increased NRM MIPSS70 high-risk group with worse OS and DFS compared with intermediate-risk group MIPSS70+ v2.0 very high-risk group with worse OS and DFS when compared with high-risk group. |
Stevens 202031 | 55 MF patients who underwent allo-HCT | 54 | MAC: 75% RIC: 25% | 10-y OS in DIPSS+ low/Int-1 risk = 82% 10-y OS in DIPSS+ Int-2/high risk = 50% 10-y PFS in DIPSS+ low/Int-1 risk = 82% 10-y PFS in DIPSS+ Int-2/high risk = 46% | ≥3 somatic mutations in addition to JAK2 or CALR2 mutation associated with worse PFS in comparison with ≤2 mutations regardless of DIPSS+ score |
Lead author/ reference . | Disease and no. of patients . | No. of genes tested . | Conditioning regimen . | Survival data . | Notes . |
---|---|---|---|---|---|
Kröger 201730 | 169 MF patients who underwent allo-HCT | 16 | MAC: 2% RIC: 98% | 5-y PFS = 48% 5-y OS = 52% | CALR mutation associated with improved OS IDH2 mutation associated with inferior RFS ASXL1 mutation associated with inferior RFS |
Tamari 201932 | 101 MF patients who underwent allo-HCT | 585 | MAC: 18% RIC: 82% | 5-y RFS = 51% 5-y OS = 52% | U2AF1 mutation associated with inferior OS and RFS DNMT3A mutation associated with inferior RFS ≥3 somatic mutations not associated with worse OS compared with ≤2 somatic mutations MAC associated with improved OS High-risk MIPSS70 not associated with inferior OS compared with intermediate-risk MIPSS70 |
Ali 201933 | 110 MF patients who underwent allo-HCT | 72 | RIC: 100% | 5-y PFS = 60% 5-y OS = 65% | CBL mutation associated with inferior OS and DFS U2AF1 mutation associated with increased NRM MIPSS70 high-risk group with worse OS and DFS compared with intermediate-risk group MIPSS70+ v2.0 very high-risk group with worse OS and DFS when compared with high-risk group. |
Stevens 202031 | 55 MF patients who underwent allo-HCT | 54 | MAC: 75% RIC: 25% | 10-y OS in DIPSS+ low/Int-1 risk = 82% 10-y OS in DIPSS+ Int-2/high risk = 50% 10-y PFS in DIPSS+ low/Int-1 risk = 82% 10-y PFS in DIPSS+ Int-2/high risk = 46% | ≥3 somatic mutations in addition to JAK2 or CALR2 mutation associated with worse PFS in comparison with ≤2 mutations regardless of DIPSS+ score |
DFS, disease-free survival; MAC, myeloablative conditioning; PFS, progression-free survival; RIC, reduced-intensity conditioning. See Tables 1 and 3 for expansion of other abbreviations.